Literature DB >> 23228304

Current issues in the management of actinic keratosis.

Roger I Ceilley1, Joseph L Jorizzo.   

Abstract

Actinic keratoses are common sun-induced skin lesions that should be treated to prevent the development of nonmelanoma skin cancer. Although cryotherapy is commonly used to treat individual lesions, it fails to address the actinically damaged field of neighboring sun-damaged skin, which is more effectively treated by field therapies to clear both visible and subclinical lesions. Most topical treatments require prolonged use and cause an inflammatory response that limits tolerability and adherence. Education is essential to teach patients about the chronic nature of actinic keratosis, the risk of nonmelanoma skin cancer, and the importance of correct use of topical medications. The addition of nonphysician clinicians to dermatologic practices provides a valuable source of education, treatment, and follow-up care to the management of actinic keratosis.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23228304     DOI: 10.1016/j.jaad.2012.09.051

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.

Authors:  Abby R Rosenberg; Mary Tabacchi; Kenneth H Ngo; Michael Wallendorf; Ilana S Rosman; Lynn A Cornelius; Shadmehr Demehri
Journal:  JCI Insight       Date:  2019-03-21

2.  Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis.

Authors:  Edward Lain; Torsten Skov; Anders Hall
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

Review 3.  Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Authors:  Spencer M Vale; Dane Hill; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

4.  Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial.

Authors:  Daniel M Siegel; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2017-12-01

5.  Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.

Authors:  Brian Berman; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Daniel M Siegel
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

6.  Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF-200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials.

Authors:  Ben Novak; Janet DuBois; Osama Chahrour; Tamara Papusha; Stefan Hirt; Thomas Philippi; Corinna Zogel; Katharina Osenberg; Beate Schmitz; Hermann Lübbert
Journal:  Clin Pharmacol Drug Dev       Date:  2021-10-11

7.  A randomized, double-blind, placebo-controlled clinical trial evaluating Dermytol(®) cream for the treatment of actinic keratoses.

Authors:  Malkanthi Evans; Douglas Kalman; Patricia Alvarez; Maryse Paquet; Najla Guthrie
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-08-07

8.  Sequential treatment of multiple actinic keratoses with solaraze and actikerall.

Authors:  Thomas Dirschka; John T Lear
Journal:  Case Rep Dermatol       Date:  2014-07-02

Review 9.  Comprehensive review on betulin as a potent anticancer agent.

Authors:  Sylwia Katarzyna Król; Michał Kiełbus; Adolfo Rivero-Müller; Andrzej Stepulak
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

10.  Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Authors:  Praven Chetty; Felix Choi; Timothy Mitchell
Journal:  Dermatol Ther (Heidelb)       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.